南模生物(688265) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter reached ¥106,937,671.62, representing a year-on-year increase of 21.52%[3] - The total profit for the third quarter was ¥8,149,982.96, with a net profit attributable to shareholders of ¥8,597,530.11[3] - Year-to-date revenue as of the reporting period was ¥302,700,815.36, showing a 14.29% increase compared to the same period last year[3] - The company reported a significant increase in net profit attributable to shareholders for the quarter, with a year-on-year growth of 242.07%[9] - Total operating revenue for the first three quarters of 2025 reached ¥302.70 million, an increase of 14.26% compared to ¥264.85 million in the same period of 2024[18] - Operating profit for the first three quarters of 2025 was ¥26.56 million, a significant turnaround from a loss of ¥20.81 million in the same period of 2024[19] - Net profit for the first three quarters of 2025 was ¥26.76 million, compared to a net loss of ¥15.20 million in the same period of 2024[19] - Basic and diluted earnings per share for the first three quarters of 2025 were both ¥0.34, recovering from a loss of ¥0.20 per share in the same period of 2024[19] Research and Development - Research and development expenses totaled ¥21,128,375.40 for the quarter, accounting for 19.76% of operating revenue, a decrease of 1.18 percentage points year-on-year[4] - Research and development expenses increased to ¥62.72 million, up from ¥57.23 million, indicating a focus on innovation[18] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥19,641,082.96[3] - The company's cash and cash equivalents as of September 30, 2025, amount to ¥123,995,787.94, down from ¥200,731,445.41 at the end of 2024[14] - Total assets as of the reporting period were ¥1,899,214,539.20, reflecting a decrease of 1.56% from the end of the previous year[4] - Total assets decreased to ¥1,899.21 million from ¥1,929.36 million, a decline of 1.56%[16] - The company's cash flow from operating activities is yet to be detailed in the provided data, indicating potential areas for future reporting[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 6,687[12] - The largest shareholder, Shanghai Dish Consulting Co., Ltd., holds 27,771,000 shares, representing 35.62% of total shares[12] - The company has not reported any changes in the top 10 shareholders due to margin trading activities[14] - There are no significant related party transactions or actions among shareholders reported[13] - The company has not received any notifications regarding other shareholders having related party relationships or acting in concert[13] Government and Market Strategy - The company expects to continue strengthening its domestic market presence, contributing to revenue growth and cost control measures[9] - Government subsidies received during the year have increased compared to the previous year, positively impacting the financial results[9] - The company is focusing on market expansion and new product development, as indicated by the increase in R&D expenses[18] Liabilities and Costs - Total liabilities decreased to ¥197.12 million from ¥246.36 million, a reduction of 20%[16] - Total operating costs decreased to ¥285.43 million from ¥296.66 million, reflecting a reduction of 3.93%[18] Cash Flow Activities - Cash inflow from operating activities totaled $283,031,576.85, an increase from $250,814,892.48 in the previous period, reflecting a growth of approximately 12.8%[22] - Net cash flow from operating activities improved to $19,641,082.96, compared to a negative cash flow of $6,582,776.74 in the prior period[22] - Cash inflow from investment activities reached $2,351,249,376.76, significantly higher than $1,663,787,664.49, marking an increase of about 41.3%[22] - Net cash flow from investment activities was negative at -$81,472,532.88, a decline from a positive cash flow of $54,334,669.66 previously[22] - Cash outflow from financing activities amounted to $14,702,993.05, down from $77,741,015.51, indicating a reduction of approximately 81.1%[23] - The net increase in cash and cash equivalents was -$77,207,060.17, compared to -$29,444,646.47 in the previous period[23] - The ending balance of cash and cash equivalents stood at $119,007,785.43, up from $68,158,274.93 at the end of the previous period[23] - The company reported a cash inflow of $2,351,180,132.49 from the recovery of investments, compared to $1,663,733,736.39 previously, reflecting a growth of approximately 41.4%[22] - Payments to employees increased to $143,887,427.60 from $136,133,446.55, representing a rise of about 5.1%[22] Accounting Standards - The company did not execute any new accounting standards or interpretations for the year 2025[24]